ISRG Stock: Intuitive Surgical BEAT Q2 2026 — So Why Did It Crash 12%? (Cheap at Last, or Value Trap?)

ManpowerGroup Stock (MAN): It Already DOUBLED — Is the Easy Money Gone? | Q2 2026 Earnings

ManpowerGroup (MAN) Q2 2026 — ManpowerGroup (MAN) reported Q2 2026: revenue $4.86B (+8% reported, +6% constant currency), ahead of the ~$4.72B estimate; adjusted EPS $0.99 (beat ~$0.96, +27% cc) and GAAP EPS $1.13 (vs a $1.44 loss a year ago) — though GAAP was flattered by a net +$0.14 of one-off items, chiefly the $88M sale of Jefferson Wells. Operating profit was $112M, a razor-thin 2.3% margin. The stock had already DOUBLED off its 52-week low of ~$25 to ~$52 (+106%) ahead of the print, spiked to a fresh 52-week high near $56 on the day, then faded to roughly flat. By region, Southern Europe is ~47% of revenue ($2.31B; France alone $1.18B) but earned just $75M of profit, while the Americas ($1.21B revenue, +14%) earned nearly as much ($72M, +99%) as U.S. profit nearly tripled; Northern Europe was barely breakeven ($2M OUP). Q3 guide: adjusted EPS $0.96–$1.06 (mid $1.01), with a 2-cent FX headwind and a 44% tax rate. Capital return was reset — the dividend was cut 53% in 2025 ($1.54 to $0.72 semi-annual, ~2.8% yield now) and buybacks are paused; net debt ~$0.86B with cash down to $181M. On mid-cycle EPS of ~$5.00 at a ~10.5x normalized P/E, our fair value is ~$52 — essentially the price. Wall Street: Hold (16 of 29), avg target ~$54. Our call: HOLD, 3/5 — a real cyclical recovery, but fully priced after a +106% double. ManpowerGroup is one of the world's largest staffing and workforce-solutions firms — ~$19B in annual revenue across 70+ countries, run through three brands (Manpower, Experis, Talent Solutions). It is a low-margin (~2% operating margin), deeply cyclical business heavily concentrated in France and Southern Europe. In Q2 2026 it posted a solid beat off a low bar: revenue $4.86B (+8% reported, +6% cc) and adjusted EPS $0.99 vs ~$0.96 expected (+27% cc), with GAAP EPS $1.13 versus a $1.44 loss a year ago — though the headline was flattered by a net +$0.14 from one-offs, mainly the $88M Jefferson Wells divestiture. The catch is the chart: the stock had already more than DOUBLED off its ~$25 low to ~$52 (+106%) in anticipation of a labor-market recovery, spiked to a 52-week high near $56 on the print, then faded to roughly flat — a classic sell-the-news move. Underneath, the recovery is real but uneven: the U.S. and Latin America are surging (U.S. operating profit nearly tripled; Other Americas revenue +29%), while France — the single largest market at $1.18B revenue — was flat with profit down 12%, and Northern Europe is barely breakeven. Capital return was reset in the downturn: the dividend was cut 53% in 2025 and buybacks paused, so the once-fat yield is now ~2.8%. And a structural question hangs over the whole industry: does AI and automation shrink staffing demand over time? For valuation we normalize a deep cyclical — mid-cycle EPS of ~$5.00 at a ~10.5x staffing multiple lands fair value near ~$52, essentially today's price (soft-cycle ~$40, recovery ~$66). Wall Street agrees it's fully valued: a Hold consensus (16 of 29) with an average target around ~$54, barely above the stock. Our call: HOLD, 3/5 — a genuine, improving recovery that is now fairly priced after a +106% run; the deep-value entry was in the $20s–$30s, and we'd want the low $40s again for a margin of safety. Not financial advice. THE CALL: HOLD (3/5, A REAL CYCLICAL RECOVERY — BUT FULLY PRICED AFTER A +106% DOUBLE OFF THE LOW) — base-case value ~$52 vs ~$52 today. What to watch: We'd get constructive again in the low $40s, where a pullback would restore a real margin of safety on mid-cycle earnings. What turns us more bullish: France and Northern Europe re-accelerating (Europe is the tell), and mid-cycle EPS proving out above $5. What breaks the thesis: hiring rolling back over into a cyclical relapse, or AI and automation structurally eroding staffing demand. Watch the constant-currency revenue and operating-unit-profit trends in Europe every quarter — the Americas are already working; Europe is the swing factor. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Alcoa Stock: AA Posted a RECORD Q2 2026 — So Why Is It Down 46%? (Bargain or Value Trap?)

Alcoa Corporation (AA) Q2 2026 — Alcoa (AA) reported a record Q2 2026: revenue $3.97B (+24% QoQ, +31% YoY, a company record), adjusted EBITDA $901M (+51% QoQ), and adjusted EPS $2.12 — but that missed the ~$2.25 Street estimate, and the stock fell ~3.4% to ~$45. GAAP EPS was $1.53 ($407M net income); the 'miss' was driven by $155M of net special items (a $123M Ma'aden mark-to-market loss and $45M on energy contracts). Under the hood it was a tale of two segments: the aluminum segment earned a RECORD $1,073M EBITDA on a record realized price of $4,752/t (+51% YoY), while the alumina segment LOST $96M with its $334/t price below a $368/t cost. Free cash flow was $422M; net debt just $873M against $1.4B cash; dividend $0.10/qtr. Alcoa also agreed to buy South32's bauxite/alumina/aluminum assets ('AliGroup') for ~$4.1B upfront plus up to $750M, and cut 2026 alumina production guidance (Pinjarra/cyclone) while holding aluminum. Our EV/EBITDA scenario work lands ~$46 on mid-cycle EBITDA (~$2.4B x 5.5x, less net debt, / 264M shares) — essentially on top of the ~$45 price. Wall Street: Buy (23 of 42), avg target ~$68.50. Our call: HOLD, 3/5 — a well-run cyclical at fair mid-cycle value, at what looks like the top of the aluminum cycle. Alcoa is one of the world's largest pure-play upstream aluminum producers — it mines bauxite, refines it into alumina, and smelts alumina into aluminum, so its profits ride two volatile commodity prices. In Q2 2026 it delivered a record quarter: revenue $3.97B (+24% QoQ), adjusted EBITDA $901M (+51% QoQ), and a record realized aluminum price of $4,752/t that drove a record $1,073M aluminum-segment EBITDA. And yet the stock sits near a 52-week low, down ~46% from its $84 high, and fell ~3.4% on the print because adjusted EPS of $2.12 missed the ~$2.25 consensus — a 'miss' created almost entirely by $155M of non-cash special items (a $123M Ma'aden mark-to-market loss and $45M on energy hedges). The tension is a commodity cyclical at what looks like a price peak: aluminum is minting money while the alumina segment loses $96M (its $334/t price is below its $368/t cost), and Alcoa is spending ~$4.1B to buy South32's bauxite/alumina/aluminum assets — doubling down on the very segment that's underwater. The balance sheet is clean (net debt $873M, $1.4B cash, $422M quarterly FCF), which buys staying power. For valuation we normalize: mid-cycle adjusted EBITDA of ~$2.4B on an EV/EBITDA scenario grid lands near $46 a share — essentially today's ~$45 price — with a wide band ($42-$51 mid-cycle, $57-$69 elevated) depending entirely on where aluminum goes. Wall Street is bullish (a Buy consensus, 23 of 42 analysts, ~$68.50 target, ~51% upside), but that target essentially requires peak aluminum prices to hold plus a premium multiple. Our call: HOLD, 3/5 — a genuinely well-run producer, fairly valued at mid-cycle after a 46% fall; we'd wait for the high $30s, near a cyclical low, for a real margin of safety. Not financial advice. THE CALL: HOLD (3/5, A WELL-RUN ALUMINUM CYCLICAL — FAIRLY VALUED AT MID-CYCLE, AT WHAT LOOKS LIKE THE TOP OF THE PRICE CYCLE) — base-case value ~$46 vs ~$45 today. What to watch: The alumina segment climbing back above breakeven and the ~$4.1B South32 (AliGroup) acquisition closing on sensible terms would turn us more constructive; conversely, a pullback into the high $30s — near a genuine cyclical low — would open a real margin of safety and move us to a buy. The thesis breaks if the record ~$4,752/t realized aluminum price mean-reverts sharply, pulling earnings and the stock down together, or if the debt-funded South32 deal levers up the balance sheet at the top of the cycle. Watch the realized aluminum price above all else. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

ISRG Stock: Intuitive Surgical BEAT Q2 2026 — So Why Did It Crash 12%? (Cheap at Last, or Value Trap?)

Intuitive Surgical (ISRG) Q2 2026 — Intuitive Surgical (ISRG) reported a clean Q2 2026 beat: revenue $2.89B (+19% YoY), non-GAAP EPS $2.80 (beat $2.48, +28%), GAAP EPS $2.29; worldwide procedures +16% (da Vinci +15%, Ion +36%); 468 da Vinci systems placed (246 were da Vinci 5) vs 395 a year ago; installed base 11,710 (+12%). Instruments & accessories $1.73B (+18%, ~60% of revenue); non-GAAP gross margin 70.0%; operating margin >40%; $8.63B cash and zero debt; $0.38B buyback. Yet the stock FELL ~12.6% to a fresh 52-week low near $352 — down ~42% from its $604 high — because FY26 da Vinci procedure-growth guidance of 13.5-15.5% marked a clear step down from the high-teens, alongside softer hospital surgery volumes and a da Vinci Class II component recall. Our owner-earnings DCF lands ~$343, essentially on top of the ~$352 price. Wall Street: Buy (39 of 56), avg target ~$525. Our call: HOLD, 3/5 — a premier compounder now at roughly fair value; not a bargain yet. Intuitive Surgical is the pioneer and monopoly of robotic-assisted surgery — the da Vinci system, the Ion lung-biopsy robot, and a razor-and-blade model where over 76% of revenue recurs. In Q2 2026 it delivered a clean beat: revenue $2.89B (+19%), non-GAAP EPS $2.80 (vs $2.48), worldwide procedures +16%, non-GAAP gross margin 70%, and 468 da Vinci placements (246 da Vinci 5), lifting the installed base 12% to 11,710. And yet the stock fell ~12.6% to a fresh 52-week low near $352 — down ~42% from its $604 high. The reason isn't the quarter; it's the guide: FY26 da Vinci procedure growth of 13.5-15.5% (management points to the midpoint) is a step down from the high-teens pace of recent years, compounded by softer hospital volumes and a Class II recall. For a stock still near 33x forward earnings, decelerating procedure growth is the number that matters most. Our owner-earnings DCF (base ~$3.2B/yr, +$8.6B net cash) spans $246-$463 across 8-10% discount rates and 10-14% growth, with a probability-weighted value near $343 — roughly on top of today's ~$352. Wall Street rates it a Buy with a ~$525 target (nearly 50% upside), but even our bullish path only reaches the mid-$400s, and on the Street's own EPS estimates the math lands near our $343. Our call: HOLD, 3/5 — a wide-moat monopoly that has finally de-rated to fair value, but is not yet a bargain. Own the quality; look to add below $300; watch the quarterly procedure line above all else. Not financial advice. THE CALL: HOLD (3/5, A PREMIER SURGICAL-ROBOTICS MONOPOLY — NOW ROUGHLY FAIR, WAIT FOR A BETTER PRICE) — base-case value ~$343 vs ~$352 today. What to watch: da Vinci procedure growth stabilizing and re-accelerating back toward the high-teens (da Vinci 5 lifting procedures per system), which would justify the premium multiple — or, conversely, a pullback below ~$300 that opens a genuine margin of safety and turns us to a buy; the thesis breaks if procedure growth slides below 12% or tariff/competition pressures compress margins Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

ABT Stock: Abbott Beat AND Raised — So Why Is It Still Down 27%? (Bargain or Value Trap?)

Abbott Laboratories (ABT) Q2 2026 — Abbott (ABT) reported a solid Q2 2026 beat: revenue $12.59B (+13.0% reported, +4.8% organic), adjusted EPS $1.31 (beat $1.28, +4% YoY), adjusted gross margin 58.0% (+100bps). Medical Devices +8.4% (CGM/FreeStyle Libre cleared $2B, +9.5%), Established Pharma +9%, Diagnostics +2.9% organic (+42.3% w/ Exact Sciences), Nutrition -3.6%. It RAISED FY26 adjusted EPS guidance to $5.45-$5.60 and reaffirmed 6.5-7.5% organic growth. Yet the Dividend King (53 yrs, $0.63/qtr) trades ~$101 — down ~27% from its $137 high — on Exact Sciences dilution/leverage (~2.7x) and NEC infant-formula litigation. Abbott is one of the great diversified healthcare compounders — Medical Devices, Diagnostics, Nutrition and Established Pharmaceuticals, anchored by the world's #1 glucose monitor (FreeStyle Libre) and 53 straight years of dividend increases. In Q2 2026 it beat (revenue $12.59B, +4.8% organic; adjusted EPS $1.31 vs $1.28) and RAISED full-year EPS guidance to $5.45-$5.60 while reaffirming 6.5-7.5% organic growth. The growth engine is diabetes care: CGM sales cleared $2B, +9.5%, with the new Libre Duo glucose-ketone sensor. Yet the stock is still down ~27% from its $137 high, de-rated to ~18x forward earnings on three overhangs: the $21B Exact Sciences acquisition (dilutive ~$0.20, leverage ~2.7x), ~1,000 NEC infant-formula lawsuits ($495M verdict under appeal), and a shrinking Nutrition segment (-3.6%). Our owner-earnings DCF lands near $110 (vs ~$101), with the bull path at ~$122 — right on the Street. Our call: BUY, 3/5 — a de-rated, wide-moat compounder that just beat and raised; quality on sale with a modest margin of safety. Accumulate on weakness in the low $90s; watch the NEC litigation and organic re-acceleration. Not financial advice. THE CALL: BUY (3/5, A DE-RATED COMPOUNDER — QUALITY ON SALE, MIND THE OVERHANGS) — base-case value ~$110 vs ~$101 today. What to watch: organic growth re-accelerating to the reaffirmed 6.5-7.5% guide (Diagnostics lapping the weak respiratory season, Nutrition stabilizing, CGM staying double-digit), the Exact Sciences deal turning accretive, and dips toward the low $90s (near the 200-day) as add points Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

GE Aerospace Stock: It Beat Earnings and RAISED Guidance Again — So Why We Say HOLD

GE Aerospace (GE) Q2 2026 — GE Aerospace (GE), the pure-play jet-engine giant carved out of the old General Electric, reported a strong Q2 2026: adjusted EPS of $2.02 beat the ~$1.86 estimate (+22% YoY) on adjusted revenue of $12.6B (+24%), orders jumped 17% to $16.5B, operating profit rose 18% to $2.7B, and free cash flow surged 43% to $3.0B. Management RAISED full-year 2026 guidance again — adjusted EPS to $7.65–$7.85 and free cash flow to $8.9–$9.2B — backed by a $210B+ backlog. The stock (~$354, up ~2.4% on the print) has nearly doubled off its $255 low and sits ~8% below its $383 high. The catch: at ~45x forward earnings and ~41x free cash flow, even our optimistic aftermarket-compounder DCF lands near $290 — below the price. Our call: HOLD. GE Aerospace is one of the market's great comeback stories — the old General Electric, broken up and reborn as a focused, ~$370B pure-play jet-engine maker led by Larry Culp. Q2 2026 was a genuinely strong quarter: adjusted EPS of $2.02 beat the ~$1.86 estimate (+22% YoY), adjusted revenue rose 24% to $12.6B, orders jumped 17% to $16.5B, free cash flow surged 43% to $3.0B, and — for the second time this year — management RAISED full-year guidance across the board (adj EPS $7.65–$7.85, FCF $8.9–$9.2B, revenue growth to the high-teens). The engine of the beat was the aftermarket: with 70,000+ engines in service (~70% of revenue is high-margin services) and a $210B+ backlog (~$170B of it contracted commercial services), GE is a razor-and-blades annuity firing on all cylinders. So the debate isn't quality — it's price. The stock has nearly doubled off its $255 low to ~$354, ~45x forward earnings and ~41x free cash flow. Even giving GE the optimistic aftermarket-compounder path (13%→7% FCF growth) AND a premium, quality discount rate, our owner-earnings DCF lands fair value near $290 — below today's price; on a textbook cost of equity (beta ~1.36) it's worth closer to the mid-$200s. A wonderful company with no margin of safety. Our call: HOLD, 3/5. We're not sellers of quality this good, but at 45x we wouldn't chase it — and we're notably more cautious than the Street's bullish ~$415 target (Buy, 24 of 35 analysts). Own it for the quality, add on real weakness in the low $300s, and watch the LEAP aftermarket. Not financial advice. THE CALL: HOLD (3/5, AN A-PLUS BUSINESS, PRICED FOR PERFECTION — A BEAT-AND-RAISE WITH NO MARGIN OF SAFETY) — base-case value ~$290 vs ~$354 today. What to watch: hard evidence the LEAP aftermarket is inflecting faster and more profitably than modeled — shop visits, spare-parts growth, and services margins accelerating together — which would justify the premium multiple and prompt an upgrade; the risk to respect is a downturn in air travel or a wave of order cancellations, which at ~45x earnings and ~41x FCF could re-rate the stock hard Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.